Company Overview - Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products [3] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and serves global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories [3] Financial Reporting - Lifecore will report its financial results for the first quarter of fiscal year 2025 on October 4, 2024, prior to market open [1] - A webcast will be hosted at 8:30 a.m. Eastern Time to discuss the financial results and recent corporate developments [1][2]

CHASKA, Minn., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that the company will participate at four upcoming industry events. Details of the company's activities at these events are as follows: Medical Aesthetic Injectable Summit 2024 Conference Date/Location: October 4-5, 2024, in Marbella, Spain Details: Darren Hieber, Lifecore's senior vice president of corporate ...

NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), of the important September 27, 2024 lead plaintiff deadline. SO WHAT: If you purchased Lifecore securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arr ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Lifecore Biomedical, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 27, 2024 [1] Group 1: Class Action Details - Investors who purchased Lifecore securities between October 7, 2020, and March 19, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [3] - The lawsuit alleges that Lifecore made false and misleading statements regarding its financial reporting and internal controls, leading to inaccurate financial statements that would need to be restated [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action litigation [4]

Installation and Qualification Successfully Completed for Closed-System Filler for Pre-Filled Syringes, Vials, and Cartridges Offers State-of-the-Art Speed and Aseptic Isolation Required for Fill/Finish of Latest Sterile Injectable Pharmaceutical and Biopharmaceutical Products Current Capacity More than Doubles with New Filler CHASKA, Minn., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO" ...

Core Viewpoint - Lifecore Biomedical, Inc. is facing a class action lawsuit due to alleged false and misleading statements regarding its financial reporting and internal controls during the class period from October 7, 2020, to March 19, 2024 [1][4]. Group 1: Class Action Details - The class action lawsuit has been filed, and investors who purchased Lifecore securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2]. - The deadline to serve as lead plaintiff in the class action is September 27, 2024, and interested parties must move the Court by this date [2]. Group 2: Allegations Against Lifecore - The lawsuit claims that Lifecore maintained deficient internal controls over financial reporting, leading to the issuance of inaccurate financial statements that would require restatement [4]. - It is alleged that Lifecore's remediation efforts regarding these deficiencies were ineffective, impairing its ability to file periodic reports with the SEC in compliance with NASDAQ requirements [4]. - The lawsuit asserts that Lifecore's financial position and prospects were materially overstated, resulting in public statements that were materially false and misleading [4]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [3]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Lifecore Biomedical, Inc. securities between October 7, 2020, and March 19, 2024, of the September 27, 2024, lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Lifecore securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by visiting the provided link or contacting the firm directly [3]. - The lawsuit alleges that Lifecore made false and misleading statements regarding its financial reporting and internal controls, which led to inaccurate financial statements that would need to be restated [5]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 for the number of settlements in 2017 and recovering over $438 million for investors in 2019 [4]. Group 3: Case Status - No class has been certified yet, meaning investors are not represented by counsel unless they retain one, and they can choose to remain absent from the class [6].

NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), of the important September 27, 2024 lead plaintiff deadline. SO WHAT: If you purchased Lifecore securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arr ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Lifecore between October 7, 2020 and March 19, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 13, 2024 (GLOBE ...

CHASKA, Minn., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that Paul Josephs, the Company's president and chief executive officer, and Ryan Lake, the Company's chief financial officer, will be the featured speakers in a fireside chat at the upcoming Craig-Hallum Bioprocessing Conference. The conference will take place virtually on September 19, 2024. ...